Insider · SEC Form 4 filer

Mark Baldry

Companies

Where they file as an insider

X4 Pharmaceuticals (XFOR) Chief Commercial Officer Latest filing May 16, 2025

Track record

Did their buys beat the typical stock?

Open-market buys3
Quarters checked 6 months later1
Beat the typical stock —
Quarters too new to check0

Too soon to tell. 1 quarter has finished so far. We show a record once 3 have.

X4 Pharmaceuticals (XFOR) Bought May 16, 2025 · $2.56K · 1,032 shares Beat typical Jun 30, 2025 $1.90 → Dec 31, 2025 $4.00 · +110.5% (typical stock +2.1%)
X4 Pharmaceuticals (XFOR) Bought Nov 15, 2024 · $4.56K · 13,404 shares Not counted Not counted. We have no fund price for this stock on both Dec 31, 2024 and Jun 30, 2025.
X4 Pharmaceuticals (XFOR) Bought May 17, 2024 · $14.7K · 21,646 shares Not counted Not counted. We have no fund price for this stock on both Jun 30, 2024 and Dec 31, 2024.

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist